News News

Sirnaomics to Present at 5th Annual Oligonucleotide & Precision Therapeutics Congress

.

Sirnaomics Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced that the company’s management will present its platform technology and discuss the potential utility of RNAi therapeutics at the 5th Annual Oligonucleotide & Precision Therapeutics Congress, taking place March 16-19 in Cambridge, Massachusetts.

Patrick Lu, Ph.D., President and Chief Executive Officer, will share the unique advantages of Sirnaomics’ proprietary polypeptide nanoparticle (PNP) drug delivery system, and discuss the company’s lead drug candidate, STP705 that is being developed as an anti-fibrosis and anti-cancer therapeutic with siRNAs targeting both TGFβ1 and Cox-2 simultaneously, resulting in human fibroblasts apoptosis. Dr. Lu will also discuss strategies for advancing multiple clinical studies ongoing in both the US and China.

The company is also developing STP707, a systemic formulation of STP705, to further advance treatment of liver fibrosis, cholangiocarcinoma and hepatocellular carcinoma. All three of these indications have received orphan drug designations by US FDA.

Dr. Lu will also introduce the company’s latest effort in development of novel RNAi therapeutics against 2019-nCoV infection using company’s proprietary respiratory aerosolization device.

Dr. Lu will be participating at the following sessions:

  • Presentation: Novel siRNA Therapeutics for Enhancing Antitumor Activity of Immune Checkpoint InhibitorDate & Time: Wednesday, March 18 at 1:50 pm ET
  • Panel Discussion: Opportunities and Challenges with RNAs
    Date & Time: Wednesday, March 18 at 2:20 pm ET

Also, Dmitry Samarsky, Ph.D., Chief Technology Officer at Sirnaomics, will chair the morning session on Tuesday, March 17 and moderate the Panel Discussion: The Future Outlook of RNA Targeted Therapeutics at 9:15 am ET the same day.

About Sirnaomics, Inc.

Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The Company’s mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. The guiding principles of the company are: Innovation, Global Vision with a Patient Centered focus. Members of the senior management team have a great deal of combined experience in the biopharmaceutical industry, financial, clinical and business management in both the USA and China. The company is supported by funding from institutional investors, corporate partnerships and government grants. Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of focus include oncology and anti-fibrotic therapeutics. Learn more at www.sirnaomics.com.